A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation

Trial Profile

A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 16 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 11 Oct 2016 Results (n=13) analysing efficacy presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top